Insights

Innovative Platform Mebias Discovery possesses a proprietary platform that enables rapid and cost-effective discovery of GPCR-targeted drugs without on-target side effects, offering a valuable opportunity for pharmaceutical partners aiming to develop safer, next-generation therapeutics.

Pipeline Progress The company's lead candidate, MEB-1170, has successfully entered Phase I clinical trials, presenting a compelling opportunity for collaborations in further clinical development, co-marketing, or licensing of this promising opioid analgesic with abuse-deterrent properties.

Funding and Support With recent investments totaling over $11 million, including grants from the NIH, Mebias demonstrates strong backing for its innovative research, making it an attractive partner for joint ventures or research collaborations focused on CNS, pain, and addiction-related markets.

Market Focus Targeting high-demand therapeutic areas such as CNS disorders, pain management, opioid use disorder, and metabolic diseases, Mebias offers strategic opportunities to engage in co-development or licensing deals within these expanding and lucrative markets.

Competitive Edge Utilizing advanced technologies like native GPCR purification and NMR, Mebias stands out in the drug discovery space, presenting potential for partners seeking innovative, precision-targeted therapeutic solutions to rapidly expand their portfolio.

Mebias Discovery, Inc Tech Stack

Mebias Discovery, Inc uses 8 technology products and services including RSS, oEmbed, Google Fonts API, and more. Explore Mebias Discovery, Inc's tech stack below.

RSS

Content Management System

oEmbed

Dev Tools

Google Fonts API

Font Scripts

JSON-LD

Javascript Frameworks

jQuery

Javascript Libraries

Java

Programming Languages

Contact Form 7

Web Platform Extensions

Apache HTTP Server

Web Servers

Mebias Discovery, Inc Email Formats	Example	Percentage
First.Last@mebiasdiscovery.com	John.Doe@mebiasdiscovery.com	50%
First.Last@mebiasdiscovery.com	John.Doe@mebiasdiscovery.com	50%

Mebias Discovery, Inc Email Formats

Example

Percentage

First.Last@mebiasdiscovery.com

John.Doe@mebiasdiscovery.com

50%

First.Last@mebiasdiscovery.com

John.Doe@mebiasdiscovery.com

50%

Frequently Asked Questions

Where is Mebias Discovery, Inc's headquarters located?

Mebias Discovery, Inc's main headquarters is located at 3001 Market Street, Suite 140. The company has employees across 1 continents, including North America.

What is Mebias Discovery, Inc's official website and social media links?

Mebias Discovery, Inc's official website is mebiasdiscovery.com and has social profiles on LinkedIn Crunchbase.

What is Mebias Discovery, Inc's SIC code NAICS code?

Mebias Discovery, Inc's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Mebias Discovery, Inc have currently?

As of December 2025, Mebias Discovery, Inc has approximately 4 employees across 1 continents, including North America. Key team members include Chief Medical Officer: S. R.President And Co-Founder: L. C. K.Managing Partner: B. T.. Explore Mebias Discovery, Inc's employee directory with LeadIQ.

What industry does Mebias Discovery, Inc belong to?

Mebias Discovery, Inc operates in the Biotechnology Research industry.

What technology does Mebias Discovery, Inc use?

Mebias Discovery, Inc's tech stack includes RSSoEmbedGoogle Fonts APIJSON-LDjQueryJavaContact Form 7Apache HTTP Server.

What is Mebias Discovery, Inc's email format?

Mebias Discovery, Inc's email format typically follows the pattern of First.Last@mebiasdiscovery.com. Find more Mebias Discovery, Inc email formats with LeadIQ.

How much funding has Mebias Discovery, Inc raised to date?

As of December 2025, Mebias Discovery, Inc has raised $11M in funding. The last funding round occurred on Oct 29, 2019 for $3.5M.

When was Mebias Discovery, Inc founded?

Mebias Discovery, Inc was founded in 2015.

Mebias Discovery, Inc

Q: How many employees does Mebias Discovery, Inc have currently?

Mebias Discovery, Inc has approximately 4 employees.

Q: What technology does Mebias Discovery, Inc use?

Mebias Discovery, Inc's tech stack includes Google Fonts API, Shopify, mod_jk, MySQL, OpenSSL.

Biotechnology ResearchPennsylvania, United States2-10 Employees

MEBIAS holds a game-changing platform to discover next generation,  GPCR drugs devoid of on-target side effects.

G-protein Coupled Receptor (GPCR) therapeutics comprise ~30% of current prescribed drugs. Mebias’ understanding of protein dynamics of GPCRs offers a unique advantage.  Given our experience and access to two key technologies – native GPCR purification and protein nuclear magnetic resonance – our approach offers resolution to identify agonists that is lacking in other methodologies.  We have delivered a series of biased mu opioid receptor scaffolds among which is an  clinical stage compound.  The Mebias platform significantly decreases the time and costs to deliver optimized leads.

Our initial areas of focus are CNS/Pain, OUD, Metabolic, and Inflammatory related disorders.


Expertise / Assets
  • Rapid identification and optimization of IND candidates devoid of on-target adverse effects, enabled by a fully validated assay suite which identifies ligand-induced dynamic conformation of GPCR signaling.
  • Differentiated mu-opioid receptor agonist (MEB-1170) for the treatment of OUD and pain (lacking respiratory depression/GI motility issues/tolerance and does not demonstrate potential for abuse liability)
Business Proposal
  • Seeking co-development and/or license our mu-opioid drug candidates 
  • Research funding/collaboration for lead discovery of additional targets in selected disease areas

Insights

Similar companies to Mebias Discovery, Inc

Incyte

Vertex Pharmaceuticals

Moderna

Alnylam Pharmaceuticals

Biogen

Gilead Sciences

Amgen